RHHVF
Roche Holding AG
Set alert
485.68 USD -1.67 -0.34%
490.00 Day range 490.00
318.81 52-week range 499.76
- YTD
- +17.62%
- 1 year
- +49.01%
- Open
- 490.00
- Prev close
- 487.35
- Mkt cap
- 386.97B
- Vol
- 38
- Avg vol
- 3.70K
- EPS
- 19.32
- P/E
- 25.14
More statistics
- Low
- 490.00
- High
- 490.00
- Earnings
- Feb 4, 2027
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 11.88.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 11.88 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | 13.42 | +0.91 | +7.27% |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 13.97 | +0.79 | +5.99% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 9.44 | +0.19 | +2.05% |
| Jul 22, 2024 | Jun 30, 2024 | 10.42 | 11.38 | +0.96 | +9.21% |
News
- Roche: Valuation Leaves Limited Upside
- Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
- Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
- Roche says divarasib cut risk of death 44% in lung cancer trial
- Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
- Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Your note
Sign in to keep a note on RHHVF — it syncs with the Stock Master app.